<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845779</url>
  </required_header>
  <id_info>
    <org_study_id>Epitope-HPV01</org_study_id>
    <nct_id>NCT01845779</nct_id>
  </id_info>
  <brief_title>Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal</brief_title>
  <acronym>Epitopes-HPV01</acronym>
  <official_title>Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complete response is a rare event in metastatic anal cancer in the case of unresectable
      recurrence after radiochemotherapy.

      In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were
      treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF (Docetaxel,
      Cisplatin and 5-Fluorouracil.

      In more than 90% of cases, anal cancers are related to Human Papilloma Virus (HPV) infection,
      that is the case of this patients for which HPV16 (human papillomavirus type 16) genotype was
      identified within the tumor samples.

      The hypothesis is that an anti-HPV response immune could be generated by chemotherapy with
      DCF and contributed to the elimination of the tumour cells and to the increase of complete
      responses. The aim to this study is to analyze immune response against HPV in this patients
      in complete response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence and characterization of anti-HPV immune responses in patients in complete remission</measure>
    <time_frame>3 months after sample</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>global survival</measure>
    <time_frame>from date to initiation of chemotherapy until the date of death for any cause assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from date to initiation of chemotherapy until the date of first documented progression, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Metastatic Anal Canal Cancer</condition>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>patients in complete response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCF regimen</intervention_name>
    <arm_group_label>patients in complete response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status ≤ 1

          -  patient with metastatic anal cancer HPV+

          -  presence of a measurable target lesion according to radiological criteria (Recist
             V1.1)

          -  patient with more than 12 months of complete remission of metastatic anal cancer
             according to radiological criteria (Recist V1.1)after treatment by DCF regimen
             (Docetaxel, Cisplatin and 5-Fluorouracil)

        Exclusion Criteria:

          -  pregnancy or lactation

          -  patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe BORG, Prof</last_name>
    <phone>+3381615615</phone>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion JACQUIN</last_name>
    <email>m1jacquin@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Oncology - University Hospital of Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BORG, Prof</last_name>
      <phone>+3381615615</phone>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion JACQUIN</last_name>
      <email>m1jacquin@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe BORG, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François BOSSET, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Nguyen, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

